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The Journal of Immunology
Dual-Specificity Phosphatase 1 and Tristetraprolin Cooperate
To Regulate Macrophage Responses to Lipopolysaccharide
Tim Smallie,*,1 Ewan A. Ross,*,1 Alaina J. Ammit,† Helen E. Cunliffe,* Tina Tang,*
Dalya R. Rosner,* Michael L. Ridley,* Christopher D. Buckley,* Jeremy Saklatvala,‡
Jonathan L. Dean,‡ and Andrew R. Clark*
Dual-specificity phosphatase (DUSP) 1 dephosphorylates and inactivates members of the MAPK superfamily, in particular, JNKs,
p38a, and p38bMAPKs. It functions as an essential negative regulator of innate immune responses, hence disruption of the Dusp1
gene renders mice extremely sensitive to a wide variety of experimental inflammatory challenges. The principal mechanisms
behind the overexpression of inflammatory mediators by Dusp12/2 cells are not known. In this study, we use a genetic approach to
identify an important mechanism of action of DUSP1, involving the modulation of the activity of the mRNA-destabilizing protein
tristetraprolin. This mechanism is key to the control of essential early mediators of inflammation, TNF, CXCL1, and CXCL2, as
well as the anti-inflammatory cytokine IL-10. The same mechanism also contributes to the regulation of a large number of
transcripts induced by treatment of macrophages with LPS. These findings demonstrate that modulation of the phosphorylation
status of tristetraprolin is an important physiological mechanism by which innate immune responses can be controlled. The
Journal of Immunology, 2015, 195: 277–288.
T
he three canonical MAPK pathways, that is, the p38
MAPK, JNK, and ERK pathways, are commonly activated
downstream of pattern recognition receptors including the
TLRs. They play critical roles in the initiation and execution of
inflammatory responses of myeloid cells (1) and have long been
considered promising targets for treatment of inflammatory pa-
thologies (2). Increasingly potent and selective MAPK inhibitors
have emerged from drug discovery programs. In combination with
genetic targeting approaches, these compounds have been useful for
the identification of mechanisms by which the MAPK pathways
control expression of inflammatory mediators. Such mecha-
nisms include the activation of downstream kinases, posttran-
scriptional regulation via the phosphorylation of RNA-binding
factors, the phosphorylation and activation of transcription factors,
cross talk with other pathways that control transcription, and
various combinations of the above. Despite some speculation
(3, 4), it is not yet clear why the evident contribution of MAPK
pathways to the inflammatory response has so far proved difficult
to translate into beneficial drugs. There is a need for greater
understanding of how the MAPK pathways are controlled and
of what are the most important mechanisms by which they in-
fluence the expression of proinflammatory and anti-inflammatory
effectors.
The two members of the ERK family, the three members of the
JNK family, and the four members of the p38 MAPK family are all
activated via phosphorylation of threonine and tyrosine residues
within a Thr–Xxx–Tyr activation motif. The amino acid (Xxx) that
separates the two phosphorylation sites is a defining characteristic
of each MAPK family. The most energy efficient means of inac-
tivating MAPKs and promoting the termination of an inflamma-
tory response is via removal of the activating phosphate groups. To
a large extent, this process is dependent on MAPK phosphatases
(MKPs), a subset of a family of enzymes known as dual-specificity
phosphatases (DUSPs), because they are able to dephosphorylate
both tyrosine- and threonine-phosphate residues (5). Mathematical
modeling of MAPK signal transduction pathways suggests that
controlling the expression of DUSPs is an important means
of determining how cells are able to respond to external stimuli
(6, 7).
In mammals, there are believed to be 10 catalytically active
MKPs, differing in their substrate specificity, subcellular locali-
zation, and pattern of expression (5). The founding member of the
family is known as MKP-1 or DUSP1. In resting cells, it is typi-
cally expressed at low or undetectable levels, but its expression is
rapidly induced by a wide variety of proinflammatory agonists,
usually in a p38 MAPK-dependent manner. Although it may target
ERK for dephosphorylation and inactivation under some circum-
stances, DUSP1 displays preference for JNK and p38 MAPK as
substrates (8). The p38-dependent expression of an enzyme that
inactivates p38 MAPK constitutes a classical negative feedback
loop, which is essential for the limitation and termination of in-
flammatory responses in vitro or in vivo (8–13). Dusp12/2 mice
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are healthy and fertile under normal conditions, but their deficit in
feedback control renders them susceptible to inflammatory chal-
lenges. They are highly sensitive to Gram-negative and -positive
sepsis (14–16), LPS-induced bone loss (17, 18), cardiac dysfunc-
tion (19), and lethal endotoxemia (20–23). In an experimental
model of rheumatoid arthritis, disease penetrance, speed of onset,
and severity of symptoms were all increased in Dusp12/2 mice
(24). Experimental colitis (25), anaphylaxis, contact hypersensi-
tivity (26), and TNF-induced systemic inflammation (27) were
also exacerbated in the absence of DUSP1. Unsurprisingly,
DUSP1 is also targeted by several proinflammatory and anti-
inflammatory agonists as a means of modulating the activity of the
p38 MAPK pathway (or other MAPK pathways) and influencing
the outcome of inflammatory challenges. Glucocorticoids (27–29),
vitamin D (30), TGF-b (31), and IL-10 (10, 32) exert anti-
inflammatory effects in part by increasing the expression of DUSP1.
On the contrary, IFN-g (33) and IL-17A (34) may prolong p38
MAPK signaling and enhance inflammatory responses via nega-
tive regulation of DUSP1.
Dysregulated responses to proinflammatory stimuli and atten-
uated effects of anti-inflammatory mediators are characteristic of
cells or mice lacking DUSP1. Yet it remains unclear exactly how
the alterations of MAPK signaling in the absence of DUSP1 lead to
increased expression of inflammatory mediators. Studies focusing
on small numbers of genes have suggested increases in tran-
scription mediated by AP-1 or NF-kB (23, 35–37), or stabilization
of mRNA mediated by the RNA-binding factor AU-rich element
binding factor 1 (38). In this study, we use a genetic approach to
demonstrate that DUSP1 controls the inflammatory response of
macrophages to LPS to a large extent by modulating the activity of
the mRNA destabilizing protein tristetraprolin (TTP).
Materials and Methods
Materials
LPS (Escherichia coli serotype EH100) was purchased from Enzo Life
Sciences. Other biochemicals were purchased from Sigma-Aldrich unless
otherwise stated. All media and sera were routinely tested for endotoxin
using the Limulus amebocyte lysate test (Lonza) and were rejected if the
endotoxin concentration exceeded 0.1 U/ml.
Generation of mouse strains
Generation of a Zfp36aa/aa mouse strain on C57BL/6 background is de-
scribed in the companion paper (39). The Dusp12/2 strain was a generous
gift from Bristol-Myers Squibb and was backcrossed to C57BL/6 for 10
generations before experiments described in this study. The double-
targeted Dusp12/2: Zfp36aa/aa line was generated by three generations of
crossing, with genotyping performed by PCR of genomic DNA, and then
was maintained as a pure-breeding line.
In vivo experiments and cell isolation
All animal experiments were approved by local ethical committees and
performed under U.K. Home Office Project Licenses. C57BL/6 mice were
purchased from Harlan Laboratories. All mice used were between 6 and
12 wk of age. To assess the systemic response to LPS, we injected mice i.p.
with 5 mg/kg purified LPS in 200 ml sterile PBS. Mice were humanely
culled 3 h after challenge, and peripheral blood was collected by cardiac
puncture for serum isolation.
Bone marrow was isolated from humanely culled mice, and bone
marrow–derived macrophages (BMMs) obtained by differentiation in vitro
with 100 ng/ml M-CSF (PeproTech) in RPMI 1640 containing 10% heat-
inactivated FCS and penicillin/streptomycin for 7 d. BMMs were plated at
a density of 1 3 106/ml in the appropriate cell culture plate at least 1 d
before stimulation. Primary peritoneal macrophages were harvested by
lavaging the peritoneal cavity with 5 ml PBS containing 2 mM EDTA.
Lavage fluid was collected and cells were resuspended at 2 3 106/ml in
DMEM supplemented with 10% heat-inactivated FCS and penicillin/
streptomycin. Cells were plated and allowed to adhere for 1 h at 37˚C,
before being washed twice with media. The remaining adherent cells were
.90% F4/80+ macrophages as assessed by flow cytometry. Cells were
rested overnight before stimulation.
Assessment of protein expression
Secreted factors in tissue culture supernatants and sera were quantified by
ELISA according to manufacturer’s instructions (eBioscience) or by using
Bio-Plex bead capture assays and a Bio-Plex 200 analyzer (Bio-Rad). Cell
lysates were resolved on SDS-PAGE gels and probed with primary Abs,
and immunoreactive proteins were visualized with HRP-coupled second-
ary Abs and chemiluminescence reagents (Bio-Rad, Pierce, or Cell Sig-
naling Technology). Primary Abs were from Cell Signaling Technology,
with the exception of an anti-TTP antiserum that was described previously
(40). Blots were visualized using the ChemiDoc MP Imaging System, and
in some cases quantified using Image Lab software (Bio-Rad).
Measurement of mRNA
RNA was extracted from BMMs using QIAshredder columns and RNeasy
Mini kit (Qiagen). cDNAwas generated using the iScript cDNA Synthesis
Kit (Bio-Rad). Gene expression was quantified by quantitative PCR on
a LightCycler 480 II (Roche) using Superscript III platinum RT-PCR kit
and custom-synthesized oligonucleotide primers (Eurofins MWG) with
SYBR Premix Ex Taq (Lonza). Relative gene expression was calculated
using the DD threshold cycle method with GapdhmRNA for normalization
of RNA levels. Primary transcript PCR was performed using primer pairs
that crossed exon-intron boundaries, with an additional DNaseI step to
remove contaminating genomic DNA from RNA samples (Qiagen). Con-
trol PCRs were carried out in the absence of RT to monitor genomic DNA
contamination, which in all cases was negligible. Sequences of oligonu-
cleotides designed to detect primary or mature transcripts are available on
request from the authors.
For microarray analysis, RNA was extracted as described earlier and
purified using RNA clean and concentrator kits (Cambridge Bioscience).
Microarray hybridization and analysis were performed by Oxford Gene
Technology Total RNA or control RNA were converted to labeled cRNA
with Cy3 or Cy5, respectively, using the Low Input Quick Amp Labeling
Kit, Two-Color (Agilent Technologies). Samples were hybridized onto
SurePrint G3 Mouse GE 8 3 60K slides and read using a G2505C scanner
(Agilent Technologies). The scanned images were analyzed with Agilent
Feature Extraction Software 10.7.3.1 using default parameters. Processed
Signal intensities were background subtracted and spatially detrended.
Statistical analysis
GraphPad Prism software (Version 5.03) was used for statistical analysis.
Unpaired, two-tailed Student t test was applied for comparison of two
groups. For analysis of multiple groups, ANOVAwas used with Bonferroni
correction for multiple comparisons. Asterisks are used throughout: *p ,
0.05, **p, 0.01, ***p, 0.005; n.s. represents not statistically significant.
Microarray analysis
Probe intensity values for the microarray were analyzed with Partek
Genomics Suite version 6.6, build 6.13.0315 (Partek). A two-way mixed-
model ANOVA was performed on the entire dataset (55681 probes) to
calculate pairwise contrasts consisting of a corrected step-up p value (false
discovery rate by the Benjamini–Hochberg step-up method integrated into
the Partek software) and a fold change or ratio for difference in gene
expression. Data from 1- and 4-h LPS treatment were analyzed separately
by ANOVA. Weakly expressed transcripts were filtered out if their log-
transformed sample intensity values did not exceed an arbitrary value of
100 in at least two of three replicate samples from LPS-treated wild type or
Dusp12/2 BMMs. Transcripts with aberrant outlying sample intensity
values (SD of three replicates . mean of three replicates) were also fil-
tered out. The microarray data described in this article have been submitted
to the Gene Expression Omnibus’s National Center for Biotechnology
Information (GSE68449; http://www.ncbi.nlm.nih.gov/).
Results
Increased mRNA stability contributes to the overexpression of
cytokines and chemokines by Dusp12/2 macrophages
As previously reported (20–23), LPS-treated Dusp12/2 BMMs
overexpressed a variety of cytokines and chemokines at both
protein and mRNA levels (Fig. 1). To identify mechanisms in-
volved in this exaggerated response, we initially focused on Tnf
and Cxcl1. Unspliced primary transcripts were quantified as
278 DUSP1 AND TTP COOPERATE TO SUPPRESS INFLAMMATION
 at U
niversity of Birm
ingham
 on Septem
ber 22, 2015
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
a means of assessing LPS-induced transcription. No differences of
Tnf transcription rates were detected between Dusp1+/+ and
Dusp12/2 BMMs, whereas in the same experiments an increase
in abundance of mature Tnf mRNA was detected in Dusp12/2
BMMs (Fig. 2A, upper panel). One hour after addition of LPS, the
levels of Cxcl1 mature transcript were 3.6-fold higher in Dusp12/2
than Dusp1+/+ BMMs (p , 0.05), whereas primary transcript was
only 1.8-fold higher (p , 0.05, Fig. 2A, lower panel).
Alterations of transcription were not sufficient to account for
the strong increases in expression of Tnf and Cxcl1 mRNAs in
Dusp12 /2 BMMs. Actinomycin D chase experiments were
therefore performed to assess mRNA stability. Both Tnf and Cxcl1
mRNAs were strongly stabilized in Dusp12/2 BMMs relative to
Dusp1+/+ controls (Fig. 2B). In macrophages of both genotypes,
a selective p38 MAPK inhibitor increased the rate of degradation
of Tnf and Cxcl1 mRNAs. Similar behavior was also observed in
the cases of Cxcl2 and Il10 mRNAs; they were more stable in
Dusp12/2 than Dusp1+/+ BMMs and were consistently destabi-
lized by inhibition of p38 MAPK (data not shown). These results
indicate that p38 MAPK-dependent mRNA stabilization contrib-
utes to the dysregulated expression of cytokines and chemokines
in macrophages lacking DUSP1.
To identify potential mechanisms of posttranscriptional dys-
regulation, we investigated the expression of selected mRNA
binding proteins in Dusp1+/+ and Dusp12/2 BMMs. HuR is an
mRNA stabilizing factor that has been implicated as a mediator of
posttranscriptional effects of the p38 MAPK signaling pathway
(41–43). TTP and butyrate response factor-1 (BRF-1) and -2 are
related mRNA-destabilizing proteins that recognize adenosine/
uridine-rich elements (AREs) in the 39 untranslated regions
(UTRs) of target transcripts and recruit components of the cellular
mRNA degradation machinery (44, 45). Downstream of p38
MAPK, MK2 phosphorylates and inactivates TTP by reducing its
affinity for AREs or preventing the recruitment of mRNA degra-
dation factors, resulting in transient and p38 MAPK-dependent
stabilization of target transcripts (46–49). Expression of HuR and
BRF-2 did not differ between Dusp1+/+ and Dusp12/2 BMMs,
but levels of both TTP and BRF-1 were higher in the latter
(Fig. 3A). The function of BRF-1 is discussed later. Here we
focus on TTP, which is encoded by the Zfp36 gene. Expression
of TTP protein was increased by a factor of 1.4 6 0.03 (n = 3)
at the 4-h time point in Dusp12/2 BMMs. Expression of Zfp36
mRNA was enhanced and prolonged in Dusp12/2 BMMs
(Fig. 3B), and its stability was increased (Fig. 3C).
Enhanced expression of certain cytokines and chemokines by
Dusp12/2 macrophages is dependent on phosphorylation and
inactivation of TTP
TTP autoregulates its expression via interaction with AREs in its
own (i.e., Zfp36) mRNA (39, 44). It is also well-known to destabilize
Tnf, Cxcl1, Cxcl2, and Il10 mRNAs (44). It therefore seems par-
adoxical that increased expression of TTP protein is accompanied
by increased stability of transcripts targeted for degradation by
TTP. However, there is a straightforward resolution to this par-
adox. It has been previously postulated, and it is conclusively
demonstrated in an accompanying article (see Ref. 39), that p38
MAPK-dependent, MK2-mediated phosphorylation of serines 52
and 178 not only inactivates TTP, but also protects TTP from
destruction by the proteasome. Activation of p38 MAPK leads to
the accumulation of TTP in an inactive form, permitting transient
stabilization of target mRNAs and expression of their protein
products. We previously created a knock-in mouse strain, in which
serines 52 and 178 of endogenous murine TTP were substituted by
nonphosphorylatable alanine residues. The mutant Zfp36aa allele
protected mice against excessive inflammatory responses to i.p.
injection of LPS. In macrophages derived from this strain, TTP
protein was constitutively degraded by the proteasome and
therefore expressed at very low levels. However, it also promoted
efficient degradation of target mRNAs because it could not be
inactivated. We hypothesized that targeted deletion of Dusp1 gives
rise to an opposite phenotype, in which the unusually prolonged
activation of p38 MAPK drives phosphorylation of serines 52 and
178, resulting in accumulation of the inactive form of TTP and
the enhanced stabilization of its target mRNAs. To test this hy-
pothesis, we generated a doubly-targeted mouse strain, in which
the disruption of the Dusp1 locus was combined with targeted
FIGURE 1. LPS-treated Dusp12/2 BMMs overexpress cytokine and chemokine mRNA and proteins. (A) Dusp1+/+ and Dusp12/2 BMMs were treated
with LPS for 4 h, and secreted cytokines and chemokines in supernatants were measured by multiplex bead capture assay. Graphs represent mean 6 SEM
of at least three independent experiments. (B) Dusp1+/+ and Dusp12/2 BMMs were treated with LPS for the times indicated and mRNAs were measured by
quantitative PCR, with normalization first against Gapdh mRNA and then against unstimulated Dusp1+/+ BMMs. Graphs represent means 6 SEM from
three to four independent experiments. *p , 0.05, ***p , 0.005.
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mutation of the Zfp36 locus. Our hypothesis predicts that mutation
of the Zfp36 locus will prevent the dysregulated expression of
cytokines and chemokines caused by Dusp1 deletion.
BMMs were prepared from mice of four genotypes: wild type
(Dusp1+/+:Zfp36+/+), Dusp12/2, Zfp36aa/aa, and Dusp12/2:
Zfp36aa/aa. MAPK signaling responses to LPS were tested
(Fig. 4A), and expression of TTP protein was assessed (Fig. 4B)
FIGURE 2. Enhanced stability of Tnf and Cxcl1 mRNAs in Dusp12/2
BMMs. (A) Dusp1+/+ and Dusp12/2 BMMs were treated with LPS for the
indicated times, RNAwas harvested, and Tnf and Cxcl1 primary and mature
(spliced) mRNAs were measured by quantitative PCR with normalization
first against Gapdh and then against levels in Dusp12/2 BMMs treated with
LPS for 60 min. Graphs show mean 6 SEM of four independent experi-
ments. (B) Dusp1+/+ and Dusp12/2 BMMs were treated with LPS for 1 h
before addition of Actinomycin D (10 mg/ml) and DRB (50 mM) to halt
transcription, in the presence of either 1 mM SB202190 or vehicle control
(0.1% DMSO). RNAwas harvested after the times indicated; Tnf and Cxcl1
mRNAs were measured by quantitative PCR with normalization first against
Gapdh and then against Tnf or Cxcl1 mRNA levels at the appropriate zero
time point. Graphs represent mean 6 SEM of three independent experi-
ments. Most error bars are obscured by symbols. *p , 0.05, ***p , 0.005.
FIGURE 3. Enhanced expression of TTP inDusp12/2BMMs. (A)Dusp1+/+
or Dusp12/2 BMMs were treated with LPS for the indicated times, whole-
cell lysates were prepared, and the ARE-binding proteins HuR, BRF1 and
BRF2 were detected by Western blotting, with actin as a loading control.
Representative of two experiments. In a separate experiment (lower two
panels), cells were identically treated and TTP was detected by Western blot-
ting, with tubulin as a loading control. Representative of five experiments.
Vertical lines indicate where lanes from a single Western blot exposure have
been spliced together. (B) Dusp1+/+ or Dusp12/2 BMMs were treated with
LPS for the indicated times, and Zfp36 mRNA was measured by quantitative
PCR with normalization first against Gapdh and then against levels in unsti-
mulated Dusp1+/+ BMMs. Graphs represent mean6 SEM of nine independent
experiments. (C) Dusp1+/+ or Dusp12/2 BMMs were treated with LPS for 1 h
before addition of Actinomycin D (10 mg/ml) and DRB (50 mM) to halt
transcription. RNAwas harvested at the indicated times and Zfp36 mRNAwas
measured by quantitative PCR with normalization first against Gapdh and then
against levels at the appropriate zero time point. Graph represents mean 6
SEM of four independent experiments. ***p , 0.005.
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by Western blotting. Phosphorylation of MK2 was measured as
a surrogate for p38 MAPK activity, which is particularly relevant
because of its link to TTP phosphorylation, stabilization, and in-
activation. The activation of all three major MAPK signaling
pathways was prolonged in Dusp12/2 BMMs, reflecting a failure
of one important off-mechanism (Fig. 4A). As previously shown
(Fig. 3A), expression of TTP protein was elevated in these cells
(Fig. 4B). In Zfp36aa/aa BMMs, the activation of MAPKs was
indistinguishable from that in wild type BMMs, but the expression
of TTP protein was markedly decreased, as described in the ac-
companying article (39). In double-mutant (Dusp12/2:Zfp36aa/aa)
BMMs, the activation of MAPKs was prolonged because of the
absence of the phosphatase, but expression of TTP protein
remained virtually as low as in Zfp36aa/aa BMMs. In other
words, the dysregulation of MAPK signaling pathways increased
the expression of TTP only if the phosphoacceptor sites S52 and
S178 were intact. Together with previously published results (50,
51), this confirms that the p38 MAPK–MK2 signaling pathway
stabilizes TTP protein via the phosphorylation of serines 52 and
178.
Tnf, Il10, Cxcl1, and Cxcl2 were all shown to be overexpressed
by Dusp12/2 BMMs, at least in part because of increased mRNA
stability. In contrast, the same transcripts were underexpressed by
Zfp36aa/aa BMMs as a consequence of decreased mRNA stability
(49). We asked which phenotype would dominate in macrophages
bearing both mutations. In other words, could the dysregulation of
MAPK signaling pathways increase the expression of these
proinflammatory and anti-inflammatory mediators if it did not
result in the phosphorylation of TTP? In a Zfp36 wild type genetic
background, disruption of the Dusp1 gene significantly increased
the expression of Tnf, Il10, Cxcl1, and Cxcl2 mRNAs as previ-
ously described. When both Zfp36 alleles were mutated, these
effects of Dusp1 gene disruption were absent (Fig. 5A). The half-
lives of Tnf, Il10, Cxcl1, and Cxcl2 mRNAs were increased in
Dusp12/2 BMMs and decreased in Zfp36aa/aa BMMs as ex-
pected (Fig. 5B). In double-mutant BMMs, the Zfp36 phenotype
dominated. Despite dysregulation of MAPK signaling pathways,
Tnf, Il10, Cxcl1, and Cxcl2 mRNAs remained unstable. At the
protein level, similar patterns were observed (Fig. 5C). Expression
of TNF, IL-10, CXCL1, and CXCL2 was elevated in LPS-treated
Dusp12/2 BMMs in comparison with wild type BMMs. In con-
trast, the expression of these cytokines and chemokines was low in
Zfp36aa/aa BMMs and was not significantly increased by addi-
tional disruption of the Dusp1 locus. Finally, mice of all four
genotypes were injected i.p. with LPS, and serum cytokine con-
centrations were measured after 3 h (Fig. 5D). Expression of TNF,
IL-10, CXCL1, and CXCL2 was higher in Dusp12/2 than wild
type mice, but similarly low in Zfp36aa/aa and double-mutant
mice. In conclusion, the disruption of the Dusp1 gene and con-
sequent dysregulation of MAPK signaling increased the expres-
sion of a set of inflammatory mediators in a manner that abso-
lutely depended on the phosphorylation of TTP serines 52 and
178. Conversely, a normal function of DUSP1 is to promote the
destabilization of certain transcripts by altering the equilibrium of
TTP phosphorylation and dephosphorylation in favor of the active,
dephosphorylated form.
Involvement of DUSP1 and TTP in the genome-wide response
to LPS
To broaden these findings and to determine how extensively
DUSP1 controls macrophage responses to LPS via modulation of
TTP phosphorylation, we assessed gene expression by microarray
in BMMs of all four genotypes after stimulation with LPS for 1 or
4 h. The LPS responses of Zfp36aa/aa BMMs were discussed in an
accompanying article (39). To our knowledge, there is no pub-
lished study describing global effects of Dusp1 gene disruption
on the LPS responses of isolated macrophages. A previous study
describing gene expression in whole spleens of Dusp12/2 mice
6 h after i.p. administration of LPS (20) is not directly comparable
with ours because of differences of experimental design, statistical
treatment, and most importantly, the complexity of cellular pop-
ulations in the spleen. More than 2000 transcripts were upregu-
lated after treatment of wild type BMMs with LPS for 1 h.
Approximately 30% of these transcripts displayed significantly
different expression in LPS-treated Dusp12/2 BMMs, a propor-
tion that changed very little if the transcripts were filtered for
increasing strength of induction by LPS (Table I). As expected, the
majority of the dysregulated response was related to increases of
gene expression in the absence of DUSP1. However, ∼5% of LPS-
induced transcripts were underexpressed by Dusp12/2 BMMs.
These included Irf1, which was expressed at 2-fold lower levels in
Dusp12/2 BMMs (p = 2 3 10212). The Irf1 gene was previously
described as being negatively regulated by p38 MAPK and con-
sequently underexpressed in Dusp12/2 cells (52). The apparent
underexpression of a set of genes in Dusp12/2 BMMs remains to
be confirmed and investigated in detail.
Microarray data from the four genotypes of macrophage were
used to investigate the functional interaction between DUSP1 and
TTP in the regulation of macrophage responses to LPS. The heat
map in Fig. 6A illustrates 445 transcripts upregulated at least
3-fold by LPS in wild type BMMs (p , 0.05), ranked according
to their expression in Dusp12/2 BMMs, with 106 significantly
overexpressed transcripts at the top and 23 significantly under-
expressed transcripts at the bottom. This pattern of underex-
pression and overexpression was disrupted by mutation of the
Zfp36aa locus (compare tracks 6 and 8). Hierarchical clustering
of the 106 overexpressed transcripts across all four genotypes
(Fig. 6B, 6C) identified two clusters (1, 2), in which disruption of
the Dusp1 gene increased expression whether the Zfp36 locus was
mutated or wild type. Cluster 3 contained 19 transcripts whose
expression was increased byDusp1 gene disruption in a manner that
strongly depended on serines 52 and 178 of TTP (Fig. 6D). These
transcripts, including Cxcl1, Cxcl2, Ier3, Il10, Tnf, and Zfp36,
FIGURE 4. Enhanced expression of TTP in Dusp12/2 BMMs is de-
pendent on intact phospho-acceptor sites S52 and S178. (A) Wild type,
Dusp12/2, Zfp36aa/aa, and Dusp12/2: Zfp36aa/aa BMMs were treated with
LPS for the times indicated; whole-cell lysates were prepared and phos-
phorylated kinases were detected by Western blotting. Representative of two
identical experiments. (B) BMMs of the same four phenotypes were stim-
ulated with LPS for 0, 4, or 8 h, lysates were prepared, and TTP protein was
detected by Western blotting. Representative of two identical experiments.
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appeared to be controlled by DUSP1 exclusively via the phos-
phorylation of TTP serines 52 and 178. Equally important, there
was a large cluster of genes (cluster 4) in which the effects of
Dusp1 gene disruption were impaired rather than completely lost
if the two phospho-acceptor sites of TTP were mutated.
These results suggest that DUSP1 regulates more than half of
the genome-wide response to LPS wholly or partly via the phos-
phorylation of TTP. To test this more rigorously, we posed the
null hypothesis that disruption of the Dusp1 gene influences the
macrophage response to LPS in a manner that is completely in-
FIGURE 5. Disruption of the Dusp1 gene enhances expression of TNF, IL-10, CXCL1, and CXCL2 in a manner that depends upon phosphorylation of
TTP. In this and subsequent figures, wild type is indicated by black, Dusp12/2 by blue, Zfp36aa/aa by orange, and Dusp12/2: Zfp36aa/aa by green. (A)
Wild type, Dusp12/2, Zfp36aa/aa, and Dusp12/2: Zfp36aa/aa BMMs were treated with LPS for 1 h, RNAwas harvested, and the indicated transcripts were
measured by quantitative PCR with normalization first against Gapdh and then against levels in unstimulated wild type BMMs. Graphs represent means 6
SEM of three independent experiments. (B) BMMs of all four genotypes were treated with LPS for 1 h before addition of Actinomycin D (10 mg/ml) and
DRB (50 mM) to halt transcription. RNA was harvested at the indicated times, and the indicated transcripts were measured by quantitative PCR with
normalization first against Gapdh and then against levels at the appropriate zero time point. Graph represents mean 6 SEM of at least three independent
experiments in each case. (C) BMMs of all four genotypes were treated with LPS for 4 h, and levels of TNF, IL-10, CXCL1, or CXCL2 proteins in
supernatants were measured by multiplex bead capture assay. Graphs represent means6 SEM of five independent experiments. In the case of CXCL2, three
of five values were outside the linear range of the multiplex assay and were arbitrarily assigned a value equivalent to the highest concentration of the
standard curve. (D) Mice of all four genotypes were injected i.p. with 10 mg/kg LPS, sacrificed 3 h later, and serum levels of TNF, IL-10, CXCL1, and
CXCL2 were measured by multiplex bead capture assay. Graphs represent mean 6 SEM of at least seven independent experiments. In the case of CXCL1,
five of eight values were outside the linear range of the multiplex assay and were arbitrarily assigned a value equivalent to the highest concentration of the
standard curve. #No statistical comparison was performed. *p , 0.05, **p , 0.01, ***p , 0.005. n.s., not statistically significant.
Table I. Genome-wide dysregulation of responses to LPS in Dusp12/2 BMMs
1 h 4 h
LPS-Induced Transcripts ↑ in Dusp12/2 ↓ in Dusp12/2 ↑ in Dusp12/2 ↓ in Dusp12/2
All 2152 499 (23%) 103 (5%) 5008 1256 (25%) 1183 (24%)
.3-fold 445 106 (24%) 23 (5%) 1479 383 (26%) 298 (20%)
.5-fold 250 56 (22%) 17 (7%) 924 229 (25%) 167 (18%)
.10-fold 143 31 (22%) 6 (4%) 481 112 (23%) 89 (19%)
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dependent of TTP phosphorylation. For each LPS-induced tran-
script, the effect of disrupting the Dusp1 locus was calculated as
the mean ratio of expression in Dusp12/2 BMMs to that in
Dusp1+/+ BMMs. In the context of a wild type Zfp36 locus, this
DUSP1 effect is referred to as DE1. In the context of a mutated
(Zfp36aa) locus, the ratio is DE2. According to the null hypoth-
esis, the effect of Dusp1 gene deletion is the same regardless of
genotype at the Zfp36 locus; that is, DE1 = DE2. In Fig. 6E, DE2
is plotted against DE1 for each of the transcripts shown in Fig. 6B.
The null hypothesis is represented by a solid diagonal line with
gradient 1.0. Some transcripts (indicated as light gray dots in
Fig. 6E) behaved exactly as predicted by the null hypothesis and
were very similarly influenced by Dusp1 gene deletion regardless
of Zfp36 genotype. Two example transcripts, Gm13889 and Errfi1,
FIGURE 6. Genome-wide effects of Dusp1 gene disruption after 1-h LPS are partly dependent on the phosphorylation of TTP. (A) BMMs of all four
genotypes were left untreated or stimulated with LPS for 1 h and subjected to microarray analysis, using three independent samples for each genotype. The heat
map represents transcripts upregulated at least 3-fold by LPS, ranked according to expression in Dusp12/2 BMMs in comparison with wild type BMMs. Blue
represents low and red represents high relative expression. (B) The 106 transcripts significantly overexpressed by Dusp12/2 BMMs were subjected to hier-
archical clustering using Genesis. (C) Patterns of relative expression within clusters 1–4 are indicated as box and whisker plots. (D) Transcripts belonging to
cluster 3 are listed. (E) For each of the 106 overexpressed transcripts shown in (B), DUSP1 effects DE1 and DE2 were calculated as described in the text and
plotted on a log 2 scale. Error was estimated by pairwise comparison of all three replicate measurements from each genotype, and on this basis a p value was
assigned for the difference between DE1 and DE2. Light gray points represent individual transcripts for which DE1 and DE2 did not differ significantly; dark
gray points represent transcripts for which DE1 and DE2 were significantly different (p, 0.01); black points represent transcripts for which DE1 and DE2 were
highly significantly different (p , 0.0001). The solid diagonal represents the null hypothesis (DE1 = DE2). The dotted line represents the best-fit regression of
all data points. (F) For selected transcripts, raw expression data from the microarray experiment are plotted as mean 6 SEM (n = 3).
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FIGURE 7. Genome-wide effects of Dusp1 gene disruption after 4-h LPS are partly dependent on the phosphorylation of TTP. (A) BMMs of all four
genotypes were left untreated or stimulated with LPS for 4 h and subjected to microarray analysis, using three independent samples for each genotype. The
heat map represents transcripts upregulated at least 3-fold by LPS, ranked according to expression in Dusp12/2 BMMs in comparison with wild type
BMMs. (B) The 383 transcripts significantly overexpressed by Dusp12/2 BMMs were subjected to hierarchical clustering using Genesis. (C) Patterns of
relative expression within clusters 1–6 are indicated as box and whisker plots. (D) For each of the 383 overexpressed transcripts (Figure legend continues)
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are indicated as open circles in Fig. 6E, and their patterns of ex-
pression are plotted in Fig. 6F. In contrast, many transcripts were
more strongly affected by Dusp1 gene disruption if the Zfp36
locus was wild type than if it was mutated (i.e., DE1. DE2). Two
examples, Tnf and Cxcl1, are indicated as open circles in Fig. 6E,
and their expression patterns plotted in Fig. 6F. The distribution of
data points below the diagonal generated a best fit regression with
gradient of 0.55 (95% confidence interval 0.42–0.67), indicated by
a dotted line in Fig. 6E, and considerably lower than the value of
1.0 predicted by the null hypothesis. A similar analysis was car-
ried out on all LPS-induced transcripts significantly overexpressed
by Dusp1+/+ BMMs, without regard to the magnitude of induction
by LPS. This analysis of 499 transcripts gave a very similar pat-
tern, with best fit regression slope of 0.53 (95% confidence in-
terval 0.47–0.59, data not shown). Likewise, the top, middle, and
bottom tertiles of transcripts in terms of strength of response to
LPS showed the same behavior (data not shown), indicating that
DUSP1 controls both weakly and strongly induced transcripts via
TTP phosphorylation.
A total of 5008 transcripts were upregulated after stimulation of
wild type macrophages with LPS for 4 h. Forty to 50% of this
response was influenced by disruption of theDusp1 locus (Table I).
Underexpression of genes in Dusp12/2 BMMs was more evident
than at the 1-h time point. Of 1479 transcripts upregulated, at least
3-fold in response to LPS, 383 (26%) were significantly overex-
pressed and 298 (20%) significantly underexpressed by Dusp12/2
BMMs (Fig. 7A; Table I). Hierarchical clustering of 383 overex-
pressed transcripts generated six discrete clusters. Three of these,
together containing 178 transcripts, were characterized by im-
pairment, ablation, or reversal of the response to Dusp1 gene
deletion in the Zfp36aa/aa background (Fig. 7B, 7C). As in the
case of 1-h stimulation, plotting DE2 versus DE1 for each tran-
script revealed a shift toward the horizontal axis (Fig. 7D), the best
fit regression having a slope of 0.64 (95% confidence interval
0.57–0.71). Again this indicates that the consequences of dys-
regulating LPS-activated MAPK signaling pathways are broadly
attenuated by targeted mutation of the Zfp36 locus. Our analyses
of transcript expression across the genome formally demonstrate
that DUSP1 regulates the macrophage response to LPS largely
(but not exclusively) via the modulation of TTP phosphorylation
(Fig. 8). In genetic terms, Zfp36 is epistatic to Dusp1.
It is clearly possible that some of the changes of gene expression
described in this study are indirect rather than direct. This applies
particularly to the 4-h time point, when there will presumably be
greater autocrine or paracrine effects of dysregulated expression of
TNF and other factors (10, 53–55). We therefore investigated the
stability of a subset of transcripts that appeared to be regulated via
the DUSP1–TTP axis at 4 h. At both 1 and 4 h, Oncostatin M
(Osm) displayed the characteristic pattern of increased expression
in Dusp12/2, but not Dusp12/2:Zfp36aa/aa BMMs. This tran-
script did not appear as a DUSP1–TTP target in the 1-h data set
because its fold induction by LPS fell short of the arbitrary 3-fold
cutoff (Fig. 7E, left). Il1b (IL-1b) was strongly upregulated by
LPS at both 1 and 4 h, but displayed the signature DUSP1–TTP
target pattern of expression only at the later time point (Fig. 7E,
right). Both of these transcripts contain multiple matches to the
consensus TTP binding sequence UAUUUAU in their 39 UTRs
(Fig. 7F). The stability of both transcripts was enhanced in
Dusp12/2, but not Dusp12/2: Zfp36aa/aa BMMs (Fig. 7G),
confirming that their decay is regulated by DUSP1 via phos-
phorylation of TTP serines 52 and 178. IL1b was previously
identified as a target of TTP (56), but to our knowledge Osm was
not. Some other transcripts (e.g., Plaur and Socs1) were increased
in Dusp12/2, but not Dusp12/2: Zfp36aa/aa, BMMs at 4 h
(GSE68449; Supplemental Table I), yet did not display corre-
sponding differences of mRNA stability (data not shown). It is
likely that the dysregulation of these transcripts is an indirect
consequence of the altered expression of TNF, or some other
factor that feeds back to influence gene expression in BMMs.
Because IL-1b has a well-established role in endotoxic shock
(57), we went back to test its expression in sera of LPS-treated
mice of all four genotypes. The predicted pattern of overex-
pression in Dusp12/2, but not Dusp12/2: Zfp36aa/aa, mice was
found (Fig. 7G). IL-1b was not detected in supernatants of LPS-
treated BMMs, presumably because of insufficient inflammasome
activation under these conditions (data not shown).
Discussion
DUSP1 is a critical negative regulator of pathological inflammatory
responses in experimental models of sepsis or endotoxic shock (8,
12–16, 20–23). Our data demonstrate that DUSP1 limits inflam-
matory responses to a large extent by controlling the activity state
of the mRNA destabilizing protein TTP (Fig. 8). Disruption of the
Dusp1 gene led to increases in the expression of inflammatory
mediators, many of which could be prevented by targeted muta-
tion of two sites of phosphorylation of TTP. Inflammatory medi-
ators controlled by this mechanism included TNF, CXCL1,
CXCL2, and IL-1b, all of which have well-established roles in
lethal systemic responses to LPS (57–60). In vitro experiments
using primary macrophages demonstrated that DUSP1 controls the
stability of proinflammatory mRNAs via modulation of TTP ac-
tivity. In vivo experiments using wild type, Dusp12/2, Zfp36aa/aa,
and Dusp12 /2; Zfp36aa/aa mice showed the physiological
shown in (B), DUSP1 effects DE1 and DE2 were calculated and plotted as in Fig. 6. The dotted line represents the best-fit regression of all data points. (E)
Patterns of expression of Osm and Il1b mRNA in BMMs of all four genotypes, as determined by microarray. (F) AREs in the 39 UTRs of murine Osm and
Il1b mRNAs. Matches to the consensus TTP binding site are indicated by horizontal bars. (G) BMMs of all four genotypes were treated with LPS for 2 h,
then Actinomycin D/DRB chases were performed as in Fig. 5. Graphs represent mean normalized mRNA levels from three independent measurements. (H)
Mice of all four genotypes were injected i.p. with 10 mg/kg LPS, sacrificed 3 h later, and serum levels of IL-1b were measured by multiplex bead capture
assay. Graph represents mean 6 SEM of at least seven independent experiments. *p , 0.05, **p , 0.01, ***p , 0.005. n.s., not statistically significant.
FIGURE 8. Schematic of the control of TTP function via phosphory-
lation and dephosphorylation, and the interaction between DUSP1 and
TTP.
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relevance of this mechanism in the context of an acute inflam-
matory response to i.p. LPS injection. For example, after i.p. in-
jection of LPS, serum levels of TNF were ∼50-fold higher in
Dusp12/2 than in Dusp12/2: Zfp36aa/aa mice.
Equivalent experiments in more complex and long-term disease
models have proved difficult because of the exaggerated inflam-
matory responses of Dusp12/2 mice. For example, we attempted
to induce arthritis by injection of arthritogenic K/BxN serum into
mice of all four genotypes. The Dusp12/2 mice developed a se-
vere, systemic inflammatory response within 3 d and had to be
culled on humane grounds. In contrast, Dusp12/2: Zfp36aa/aa
mice developed and then resolved arthritis over 22 d, without
evidence of systemic inflammation (data not shown). These in-
complete observations illustrate the central role of DUSP1 in
limiting inflammatory responses, and the difficulty of investigating
mechanisms directly in the Dusp12/2 mouse. They also support
the contention that the hyperinflammatory phenotype of the
Dusp12/2 mouse is largely a consequence of inactivation of TTP.
The functional cooperation between DUSP1 and TTP is illustrated
schematically in Fig. 8. The induction of DUSP1 expression in
response to a proinflammatory stimulus constitutes a negative
feedback loop, assisting in the deactivation of MAPK p38. The
DUSP1-mediated decline in MAPK p38 activity results in a shift
in the equilibrium from phosphorylated (inactive) to dephos-
phorylated (active) TTP. The consequent increase in the mRNA
destabilizing activity of TTP drives the off-phase of expression of
inflammatory mediators.
It has been previously reported that Dusp12/2 macrophages
overexpress IL-10, as well as proinflammatory cytokines (23). We
show in this study that Il10 mRNA is subject to exactly the same
DUSP1–TTP-mediated regulation as the proinflammatory tran-
scripts Tnf, Cxcl1, Cxcl2, and Il-1b. This illustrates the point that
the initiation and resolution of inflammation are often mechanis-
tically coupled; in the words of Serhan and Savill, “The beginning
programs the end” (61). Nevertheless, the overexpression of IL-10
in the absence of DUSP1 is insufficient to prevent excessive in-
flammatory responses in vivo, perhaps because of its delayed
production, or simply because the proinflammatory drive becomes
overwhelming (23).
According to microarray data, up to 50% of the enhanced re-
sponse of Dusp12/2 macrophages to LPS was significantly im-
paired by mutation of TTP phospho-acceptor sites. These data
should prove a useful starting point for the identification of novel
targets of the DUSP1–TTP regulatory access. As an example, we
showed that Osm mRNA was regulated by DUSP1 via the phos-
phorylation of TTP, although it remains to be confirmed that its
protein product is regulated in the same manner. Osm encodes
Oncostatin M, a member of the IL-6 family that has proin-
flammatory functions and has been implicated in pathogenesis of
rheumatoid arthritis and other inflammatory conditions (62).
However, some caution needs to be applied to the analysis of
microarray data because of the potential for indirect autocrine or
paracrine effects (10, 53–55). The transcripts Plaur and Socs1
were overexpressed by Dusp12/2, but not Dusp12/2 ; Zfp36aa/aa,
BMMs, yet there was no evidence of differences in mRNA decay.
Plaur mRNA decayed equally slowly, whereas Socs1 mRNA
decayed equally rapidly in BMMs of all four genotypes (data
not shown). Neither of these transcripts contains a canonical
UAUUUAU binding site for TTP. We therefore suspect that the
dysregulation of these genes is a secondary phenomenon. It may
be wisest to combine microarray data mining with analysis of
mRNA sequences of putative targets or with RNA immunopre-
cipitation assays (44).
Clearly, not all of the enhanced LPS responses of Dusp12/2
macrophages are dependent on altered TTP function. Increased
mRNA expression may be partly due to enhanced transcription, as
has been suggested by others (23, 35–37). It was also noted that
expression of the TTP family member BRF-1 was elevated in
LPS-treated Dusp12/2 macrophages. The genes encoding TTP
and BRF-1 have diverged since a duplication at least 400 million
years ago. One site of MK2-mediated phosphorylation remains
conserved in BRF-1 and has been shown to mediate modulation of
BRF-1 function by the MAPK p38-MK2 signaling cascade (63).
Whether phosphorylation and inactivation of BRF-1 contributes to
the Dusp12/2 phenotype cannot yet be directly tested.
Results presented in this article confirm the hypothesis (50, 51)
that phosphorylation of serines 52 and 178 protects TTP from
degradation by the proteasome. Dysregulated MAPK p38 signal-
ing in Dusp12/2 macrophages increased the expression of TTP
protein only if those phosphorylation sites were intact. It was
recently reported that unstructured domains of TTP promote its
recognition and destruction by the proteasome (64). Perhaps phos-
phorylation prevents this process by imposing structure, for ex-
ample, via interaction of phosphorylated TTP with 14-3-3 proteins
(44). A consequence of coupled stabilization and inactivation is
that the activity and the expression of TTP are inversely related.
For example, TTP protein levels were high but activity was low in
Dusp12/2 macrophages, whereas TTP protein levels were low but
activity was high in either Zfp36aa/aa or Dusp12/2: Zfp36aa/aa
macrophages. In other words, TTP may be most evident where it
is least active and most active where it is least evident. It follows
that when strong expression of TTP is found at sites of inflam-
mation in vivo, this may be symptomatic of a resolution process
that is failing rather than an active, ongoing downregulation of
inflammatory mediators. Strong expression of TTP has been de-
scribed in atherosclerotic plaques (65) and rheumatoid synovia
(66). We hypothesize that in these contexts, TTP is predominantly
phosphorylated at serines 52 and 178 and therefore inactive, and
furthermore that its inactivation contributes to the chronically
inflamed state.
In summary, in this study, we have used genetic tools to identify
a pathway that tightly regulates expression of a set of key proin-
flammatory and anti-inflammatory mediators in primary macro-
phages, and contributes to the regulation of many more mediators
of the inflammatory response. The principal function of this
pathway is to promote the off phase of the macrophage response to
a proinflammatory stimulus, and presumably to assist in resolution
of inflammation. We speculate that defects in the function of this
pathway could contribute to chronicity of inflammatory disease.
Furthermore, we speculate that therapeutic targeting of the
DUSP1–TTP pathway might be used to exert anti-inflammatory
effects.
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